Meta Rally and Cheaper Oil Lift Stocks as AMD Hits $1 Trillion
Meta’s Muse drew investor demand as easing crude prices helped stocks, while AMD joined the trillion-dollar club on Monday.

Stocks, crypto, commodities and the economy. Short, sourced stories, updated around the clock.
82 stories in the last 24 hours
Updated 9:38 AM (Times shown in New York time (ET))
Page 25 of 43 · 1,015 stories
Meta’s Muse drew investor demand as easing crude prices helped stocks, while AMD joined the trillion-dollar club on Monday.

SHIB’s huge circulating supply makes a dollar price extraordinarily difficult to justify, even if another crypto bull market lifts demand.

A Motley Fool model points to $1,790 by end-2027, but relies on analyst sales forecasts and a hypothetical 30% operating margin.

The partnership lets Muse users buy from Shopify merchants through Shop Pay, extending Meta’s new assistant from product discovery into checkout.

The partnership will let eligible businesses use approved financing for supplier bills and operating costs, starting with Upfront customers in the UAE.

A new Alchemy partnership lets AI agents buy online under user-set limits, while Mastercard’s BVNK deal extends its bet on digital payments.

American, United and Southwest are rethinking flights as higher fuel bills threaten margins and leave travelers with fewer holiday options.

A Motley Fool contributor sees ASTS leading space stocks next year, but the forecast depends on launches, testing and paying customers.

Aramco has alerted Asian refiners to possible Yanbu cargoes, while the pipeline restart begins at a low rate and full recovery may take weeks.

U.S. futures barely moved after a record-setting tech session, while conditional reopening news pushed crude prices down about 2%.

Oil slid on a conditional Iranian offer to reopen the Strait of Hormuz, while U.S. equity futures showed only modest gains.

Stifel sees nearly $9 billion in ownership-adjusted sales by 2037, but Roivant must now prove it can turn a new approval into revenue.

A rising share of companies trimming payouts is drawing attention to cash-flow pressure, even as a cut can have company-specific reasons.

AbbVie offers faster-growing drug sales and a rising payout, while Pfizer’s much higher yield comes with a tougher recovery to prove.

Bunge shares have returned nearly twice as much as the S&P 500 so far in 2026, despite a sharp one-day drop.

Bitcoin touched its highest price since January, but fast-growing futures bets and weak U.S. buying leave the rally short of confirmation.

The chipmaker is expanding capacity for advanced chips, but investors must weigh future sales against heavier spending and margin pressure.

The five-year estimate assumes VFVA repeats its recent gains, but Vanguard’s longer-term outlook suggests investors should temper expectations.

The FDA approval opens a route to sales, while a failed Angelman trial and ongoing losses complicate Ultragenyx’s path to profitability.

Bank of America survey finds younger adults more likely to see wagers as investing, while payment data show money flowing back falls short.

Thirty-year yields remain near recent highs, giving income investors a stronger bond alternative while raising borrowing costs across the economy.

The agreement connects Twist’s lab services with Lilly’s AI models, but neither company disclosed financial terms or projected revenue.

U.S. banks are helping Chinese tech firms raise billions as Chinese investors increase exposure to American AI and chip companies.

The Brazil mine study lifts Meridian’s estimated project value, but construction still depends on financing and a key permit.
